Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

OBJECTIVE: We aimed to carry out a "real world" comparison of bivalirudin plus unfractionated heparin (UFH) versus abciximab plus UFH in patients undergoing primary percutaneous coronary intervention (PPCI) for ST elevation myocardial infarction (STEMI). METHODS: We included patients who had abciximab or bivalirudin during their PPCI in our unit between Sept 2009 and Nov 2011. RESULTS: The study included 516 and 484 patients in the bivalirudin and abciximab group respectively. There were more women in the bivalirudin group (29% vs 20%, p 0.001), while cardiogenic shock (6.4% vs 10.1%, p 0.04) and thrombectomy device use (76.6% vs 82%, p 0.04) were lower in the bivalirudin group. The primary composite end point of 30-day mortality, 30-day definite stent thrombosis or non-CABG major bleeding was similar between the bivalirudin and abciximab groups (7.8% vs 9.5%, OR 0.8, 95% CI 0.5 to 1.2, p 0.4). There was also no difference in in-hospital mortality (4.1% vs 4.3%, p 0.9), 30-day mortality (5.2% vs 6.4%, p 0.5), 1-year mortality (9.1% vs 9.9%, p 0.7), 30-day stent thrombosis (1% vs 0.4%, p 0.5) and non-CABG bleeding (2.7 vs 3.7%, p 0.4) between the bivalirudin and abciximab group respectively. On Cox proportional hazard analysis after adjusting for all the co-variates, the use of bivalirudin was not a predictor of 30-day mortality (HR 1.13, 95% CI 0.7-1.9, p 0.7). CONCLUSION: In this "real-world" observational study, there was no significant difference in the clinical outcome of PPCI for patients who had abciximab or bivalirudin after initial pre-treatment with UFH.

Original publication

DOI

10.1016/j.carrev.2013.07.006

Type

Journal article

Journal

Cardiovasc Revasc Med

Publication Date

2013

Volume

14

Pages

289 - 293

Keywords

Adjunctive therapy, GP2b3a inhibitor, HORIZONS-AMI, STEMI, Abciximab, Aged, Antibodies, Monoclonal, Anticoagulants, Antithrombins, Coronary Thrombosis, Drug Therapy, Combination, Female, Hemorrhage, Heparin, Hirudins, Hospital Mortality, Humans, Immunoglobulin Fab Fragments, Kaplan-Meier Estimate, Logistic Models, Male, Middle Aged, Myocardial Infarction, Peptide Fragments, Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors, Platelet Glycoprotein GPIIb-IIIa Complex, Proportional Hazards Models, Recombinant Proteins, Retrospective Studies, Risk Factors, Time Factors, Treatment Outcome